thiodiglycolic anhydride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: thiodiglycolic anhydride
• 英文别名: 2,2'-thiodiglycolic anhydride；2-[2-[2-[Carboxy(hydroxy)methyl]sulfanyl-2-hydroxyacetyl]oxy-1-hydroxy-2-oxoethyl]sulfanyl-2-hydroxyacetic acid
• 化学式: C₈H₁₀O₁₁S₂
• 分子量: 346.293
• InChiKey: RXJFLVNTAOZIOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  250
• 氢给体数：
  6
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  thiodiglycolic anhydride 生成 2-((2-(octadecyloxy)-2-oxoethyl)thio)acetic acid
  参考文献：
  名称：

  PEG LIPIDS AND USES THEREOF

  摘要：

  本公开部分提供了化合物（即PEG脂质），这些化合物在制药组合物、化妆品组合物和药物递送系统中非常有用，例如用于脂质纳米粒（LNP）配方。本公开还提供了包含此处所述PEG脂质的LNP配方以及使用它们的方法。例如，此处提供的LNP对于将药物（例如治疗药物）递送到主体中非常有用。在某些实施例中，此处提供的PEG脂质和LNP表现出比现有的PEG脂质和LNP配方更高的PEG脱落。

  公开号：

  US20220047518A1

文献信息

• BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS
  申请人：Kondo Kazumi

  公开号：US20110071084A1

  公开（公告）日：2011-03-24

  The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R 1 represents a —CO—(CH 2 ) n —COR 2 group (wherein n is an integer of 1 to 4, and R 2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.

  本发明提供了一种苯哌啶化合物，可以长时间维持托瑞那汀的血药浓度，从而实现所需的药效。本发明的苯哌啶化合物由通式（1）表示，其中R1代表一个—CO—(CH2)n—COR2基团（其中n为1至4的整数，R2为(2-1)一个羟基；(2-2)一个可选择地取代有羟基、较低烷氧基、较低烷酰基、较低烷酰氧基、较低烷氧羰氧基、环烷氧羰氧基或5-甲基-2-氧代-1,3-二氧代-4-基的较低烷氧羰氧基；或(2-3)一个可选择地取代有羟基较低烷基基团的氨基），等等。
• [EN] POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT<br/>[FR] COMPOSITION POLYMÉRISABLE COMPRENANT UN SULFONATE D'OXIME EN TANT QU'AGENT DE DURCISSEMENT THERMIQUE
  申请人：BASF SE

  公开号：WO2012101245A1

  公开（公告）日：2012-08-02

  The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QAaBbCc where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a + b + c is 1, 2, 3, 4 or 6 where (A) is a group (B) is a group (C) is a group where # denotes the point of attachment to Q; X is S or NR14 and Q, R1, R2, R3 and R14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

  本发明涉及一种可聚合的组成，包括至少一种乙炔基不饱和的可聚合化合物和至少一种具有公式（I）QAaBbCc的亚硝基亚磺酸酯化合物，其中a为0、1、2、3、4或6，b为0、1、2、3、4或6，c为0、1、2、3、4或6，其中a+b+c的总和为1、2、3、4或6，其中（A）是一个基团，（B）是一个基团，（C）是一个基团，其中#表示与Q连接的点；X是S或NR14，Q、R1、R2、R3和R14如权利要求1和说明书中所定义。本发明还涉及使用这种组成物，新型亚硝基亚磺酸酯及其作为热固化促进剂的应用。
• [EN] MACROMOLECULES OF DENDRIMER-PLATINUM CONJUGATES<br/>[FR] MACROMOLÉCULES DE CONJUGUÉS DENDRIMÈRE-PLATINE
  申请人：STARPHARMA PTY LTD

  公开号：WO2015035446A1

  公开（公告）日：2015-03-19

  The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least one platinum-containing moiety is attached. In particular embodiments, the macromolecule has a plurality of platinum-containing moieties attached to the surface amino groups. In another particular embodiment, the macromolecule comprises a dendrimer having surface amino groups to which at least two different moieties are attached, a first moiety being a platinum-containing moiety and the second moiety being a pharmacokinetic modifying agent or targeting agent. Pharmaceutical compositions comprising the macromolecules and uses of the macromolecules for treating or suppressing the growth of a cancer is also described.

  本发明涉及一种包括具有表面氨基团的树枝状分子的大分子，其中至少连接有一个含铂基团。在特定实施方式中，该大分子具有连接到表面氨基团的多个含铂基团。在另一特定实施方式中，该大分子包括具有表面氨基团的树枝状分子，其中至少连接有两种不同的基团，第一种基团是含铂基团，第二种基团是药代动力学改性剂或靶向剂。还描述了包括这些大分子的药物组合物以及这些大分子用于治疗或抑制癌症生长的用途。
• Nitric oxide donors, compositions and methods of use related applications
  申请人：——

  公开号：US20030203915A1

  公开（公告）日：2003-10-30

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

  该发明描述了新颖的一氧化氮供体和至少含有一个一氧化氮供体的新型组合物。该发明还提供了至少含有一个一氧化氮供体的新型组合物，以及可选地至少含有一个治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病的方法，用于抑制血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由于异常细胞增殖导致的病理状况；移植排斥、自身免疫、炎症、增殖、过度增殖、血管疾病；用于减少瘢痕组织或抑制伤口收缩，特别是通过给予一氧化氮供体的预防性和/或治疗性治疗以及至少一个治疗剂的组合来治疗再狭窄的方法。该发明还提供了治疗炎症、疼痛、发热、胃肠道疾病、呼吸道疾病和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内源性内皮血管舒张因子的水平，并/或刺激内源性一氧化氮的合成和/或是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地将一氧化氮传递或转移至靶向部位。治疗剂可以选择性地用至少一个NO和/或NO2基（即亚硝基化和/或亚硝化）替代。该发明还提供了至少含有一个一氧化氮供体和/或至少一个治疗剂的新型组合物和试剂盒。
• [EN] DENDRIMER FORMULATIONS<br/>[FR] FORMULATIONS DE DENDRIMÈRES
  申请人：ASTRAZENECA AB

  公开号：WO2020035815A1

  公开（公告）日：2020-02-20

  Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.

  公开了包含公式（I）的冻干化合物或其药用盐的药物组合物，以及使用它们治疗癌症的方法。